Long-term response to galantamine in relation to short-term efficacy data: Pooled analysis in patients with mild to moderate Alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 2, 2011, Pages 175-186

  Kavanagh, S ^a   Howe, I ^b   Brashear, H R ^a,c   Wang, D ^a,c   van Baelen, B ^d   Todd, M ^c   Schwalen, S ^a,e,f  

^a JOHNSON AND JOHNSON   (United States)

^b Shire Pharmaceuticals   (United Kingdom)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d SGS Medisearch International NV   (Belgium)

^e JANSSEN CILAG GMBH   (Germany)

^f GRÜNENTHAL GMBH   (Germany)

Author keywords

Alzheimer's disease; Cognition; Dementia; Galantamine

Indexed keywords

GALANTAMINE; PLACEBO;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CHRONIC DRUG ADMINISTRATION; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; TREATMENT DURATION;

EID: 79954503754     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720511795256044     Document Type: Article

References (21)

1. Reminyl Tablets, SPC from the eMC. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=10335. Accessed 31 March 2008.
2. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 16: 852-857 (2001).
3. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 71: 589-595 (2001).
4. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261-2268 (2000).
5. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269-2276 (2000).
6. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321: 1445-1449 (2000).
7. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 20: 120-132 (2005).
8. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359: 1283-1290 (2002).
9. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 12: 473-482 (2004).
10. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 11: 734-741 (2004).
11. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 61: 252-256 (2004).
12. Feldman HH, Pirtilla T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 24: 479-488 (2009).
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
14. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250-260 (1993).
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
16. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364 (1984).
17. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151: 390-396 (1994).
18. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115 (2004).
19. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070 (2009).
20. Feldman HH, Van Baelen B, Kavanagh SM, Torfs KE. Cognition, function, and caregiving time patterns in patients with mild-tomoderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 19: 29-36 (2005).
21. Matthews F. Review of memantine submission, and detailed investigation of submissions for donepezil, rivastigmine and galantamine including new analyses. 2006. Available at: http://www.nice.org.uk/nicemedia/pdf/AD_ER_TR_No_2_B1.pdf. Accessed 10 May 2010.